Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13292426 | 0.86 | ADRB1 (0.77) | ADRB1ADRB2 | |
| SCHEMBL17481986 | 0.82 | ADRB1 (0.47) | ADRB1ADRB2 | |
| SCHEMBL17476277 | 0.82 | ADRB2 (0.49) | ADRB1ADRB2 | |
| SCHEMBL17476273 | 0.81 | SMYD3 (0.44) | ADRB1ADRB2 | |
| SCHEMBL17476311 | 0.81 | SMYD3 (0.44) | ADRB1ADRB2 | |
| SCHEMBL17476275 | 0.81 | SMYD3 (0.44) | ADRB1ADRB2 | |
| Hydrochloric Acid SCHEMBL17476307 | 0.80 | ADRB2 (0.46) | ADRB1ADRB2 | |
| Hydrochloric Acid SCHEMBL11031532 | 0.79 | ADRB1 (1.00) | ADRB1ADRB2 | |
| SCHEMBL22864254 | 0.79 | ADRB2 (0.53) | ADRB1ADRB2 | |
| SCHEMBL24630986 | 0.79 | ADRB1 (0.46) | ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2021003161-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | ADRB1 2/4885ADRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.